AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36405056 — intervention group
Group type: EXPERIMENTAL
Intervention: Date palm pollen (DPP) supplementation (300 mg per day for 35 days)
Number of subjects: 68
Study 36405056 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch capsule)
Number of subjects: 68
Study 32966810 — intervention group
Group type: EXPERIMENTAL
Intervention: Surufatinib (300 mg, orally once per day)
Number of subjects: 172
Study 32966810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 32966810 — intervention group
Group type: EXPERIMENTAL
Intervention: Surufatinib
Number of subjects: 172
Study 33205673 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP) at a fixed dose of 25 mg/m2/day
Number of subjects: 952
Study 33205673 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP) escalation (up to 50 or 75 mg/m2/day)
Number of subjects: 952
Study 33205673 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD-MTX), asparaginase, and vincristine
Number of subjects: 952
Study 35811477 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-weeks exercise-based cardiac rehabilitation including a psycho-educational programme
Number of subjects: 147
Study 35811477 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 147
Study 34183256 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (new approach to secure PVC with surgical knot and elastic adhesive bandage)
Number of subjects: 248
Study 34183256 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard approach using sterile, transparent, and protective film)
Number of subjects: 248
Study 35849787 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen
Number of subjects: 494
Study 35849787 — intervention group
Group type: COMPARATOR
Intervention: VenturiMask oxygen
Number of subjects: 494
Study 32449010 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated deep transcranial magnetic stimulation (adTMS) for 10 days
Number of subjects: 28
Study 32449010 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated deep transcranial magnetic stimulation (adTMS) for 15 days
Number of subjects: 28
Study 32449010 — intervention group
Group type: EXPERIMENTAL
Intervention: adTMS (both protocols)
Number of subjects: 28
Study 32507128 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone PR tablet with naltrexone (T+)
Number of subjects: 24
Study 32507128 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone PR tablet without naltrexone (T)
Number of subjects: 24
Study 32507128 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygesic PR tablet with naltrexone (R+)
Number of subjects: 24
Study 32507128 — intervention group
Group type: COMPARATOR
Intervention: Oxygesic PR tablet without naltrexone (R)
Number of subjects: 24
Study 616173046 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (D, 0.25 mg)
Number of subjects: 165
Study 616173046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (I, 15 mg)
Number of subjects: 165
Study 616173046 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-receiving both drugs)
Number of subjects: 165
Study 36001052 — intervention group
Group type: EXPERIMENTAL
Intervention: MyJourney online self-guided psychosocial intervention
Number of subjects: 235
Study 36001052 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 235
Study 32840169 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention
Number of subjects: 0
Study 32840169 — intervention group
Group type: COMPARATOR
Intervention: No-affirmation control
Number of subjects: 0
Study 32740086 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing factor (CRF) 100 μg
Number of subjects: 21
Study 32740086 — intervention group
Group type: COMPARATOR
Intervention: 5-mL saline solution (placebo)
Number of subjects: 21
Study 35073958 — intervention group
Group type: EXPERIMENTAL
Intervention: HVOPM+NOx
Number of subjects: 19
Study 35073958 — intervention group
Group type: EXPERIMENTAL
Intervention: HVONOx
Number of subjects: 19
Study 35073958 — intervention group
Group type: COMPARATOR
Intervention: FA
Number of subjects: 19
Study 34420346 — intervention group
Group type: EXPERIMENTAL
Intervention: First method based on Hankel matrices; provides a family of entanglement criteria; lowest order reduces to p_{3}-positive-partial-transpose criterion.
Number of subjects: 0
Study 34420346 — intervention group
Group type: EXPERIMENTAL
Intervention: Second method; optimal entanglement detection method.
Number of subjects: 0
Study 32682929 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of vitamin C daily for 30 days
Number of subjects: 36
Study 32682929 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g of NAC daily for 30 days
Number of subjects: 36
Study 32682929 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of vitamin C
Number of subjects: 36
Study 32682929 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g of NAC
Number of subjects: 36
Study 32682929 — intervention group
Group type: COMPARATOR
Intervention: 1 g of vitamin C and 1.2 g of NAC
Number of subjects: 36
Study 35413719 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (1.2 g daily)
Number of subjects: 528
Study 35413719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 528
Study 34089564 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdermabrasion (MDA) combined with glycolic acid 70% (GA70%) peel
Number of subjects: 30
Study 34089564 — intervention group
Group type: COMPARATOR
Intervention: Glycolic acid 70% (GA70%) alone
Number of subjects: 30
Study 35906473 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin supplementation (13 g of extracted inulin powder from Thai Jerusalem artichoke)
Number of subjects: 155
Study 35906473 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric maltodextrin
Number of subjects: 155
Study 35906473 — intervention group
Group type: COMPARATOR
Intervention: Dietary fiber advice
Number of subjects: 155
Study 34628384 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic training (main group, 29 patients)
Number of subjects: 47
Study 34628384 — intervention group
Group type: COMPARATOR
Intervention: Simulated training (control group, 18 patients)
Number of subjects: 47
Study 32631414 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized PEEP (iPEEP) determined by Cstat-directed PEEP titration
Number of subjects: 80
Study 32631414 — intervention group
Group type: COMPARATOR
Intervention: PEEP of 5 cmH2O (PEEP5 group)
Number of subjects: 80
Study 32631414 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard lung-protective ventilation methods (low tidal volumes, fraction of inspired oxygen ≥ 0.5, recruitment maneuvers)
Number of subjects: 80
Study 35241937 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing Exercises, Foot Reflexology, and Massage (BRM)
Number of subjects: 225
Study 33346674 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing Hearts Together (HHT) intervention
Number of subjects: 78
Study 34655014 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume group received 3600 mL of lactated Ringer's solution (LRS) in 24 hours starting 2 hours before the ERCP.
Number of subjects: 200
Study 34655014 — intervention group
Group type: COMPARATOR
Intervention: Control group received maintenance fluid hydration calculated by the Holliday-Segar method.
Number of subjects: 200
Study 34655014 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume group
Number of subjects: 200
Study 34655014 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 33077680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous t-PA
Number of subjects: 0
Study 33077680 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 33077680 — intervention group
Group type: COMPARATOR
Intervention: DAPT
Number of subjects: 0
Study 32347139 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard FEC chemotherapy (600/60/600 mg/m2)
Number of subjects: 1452
Study 32347139 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy-induced leukopenia
Number of subjects: 1452
Study 34783687 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood violent crime victimization (objective and subjective measures)
Number of subjects: 0
Study 34783687 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of community well-being and support
Number of subjects: 0
Study 34867514 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) for 40 days
Number of subjects: 120
Study 34867514 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological Intervention (PI) for 40 days
Number of subjects: 120
Study 34867514 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Intervention (CI) for 40 days
Number of subjects: 120
Study 34867514 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 35025757 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Hyaluronic Acid cream
Number of subjects: 168
Study 35025757 — intervention group
Group type: COMPARATOR
Intervention: Neutral comparator cream (identical cream without HA)
Number of subjects: 168
Study 32552711 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular stem (50 ABG II stems with modular necks)
Number of subjects: 75
Study 32552711 — intervention group
Group type: COMPARATOR
Intervention: Standard stem (25 standard stems)
Number of subjects: 75
Study 35363058 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Walking Program (MWP) - eight weekly sessions
Number of subjects: 55
Study 35363058 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 55
Study 34486320 — intervention group
Group type: EXPERIMENTAL
Intervention: Growing media composition of 25% soil, 25% rice husk charcoal, 50% organic plus fertilizer (M5)
Number of subjects: 0
Study 34486320 — intervention group
Group type: EXPERIMENTAL
Intervention: Growing media compositions of 50% soil, 0% rice husk charcoal, 50% organic plus fertilizer (M2)
Number of subjects: 0
Study 34486320 — intervention group
Group type: EXPERIMENTAL
Intervention: Growing media compositions of 50% soil, 50% rice husk charcoal, 25% organic plus fertilizer (M4)
Number of subjects: 0
Study 34486320 — intervention group
Group type: EXPERIMENTAL
Intervention: Growing media compositions of 25% soil, 50% rice husk charcoal, 25% organic plus fertilizer (M7)
Number of subjects: 0
Study 34486320 — intervention group
Group type: EXPERIMENTAL
Intervention: Growing media compositions of 0% soil, 50% rice husk charcoal, 50% organic plus fertilizer (M8)
Number of subjects: 0
Study 34817440 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-wire snare (0.30 mm)
Number of subjects: 660
Study 34817440 — intervention group
Group type: COMPARATOR
Intervention: Thick-wire snare (0.47 mm)
Number of subjects: 660
Study 32052516 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (DAPA) 10 mg + Saxagliptin (SAXA) 5 mg
Number of subjects: 444
Study 32052516 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (GLIM) 1-6 mg (titrated)
Number of subjects: 444
Study 32052516 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (DAPA) + Saxagliptin (SAXA)
Number of subjects: 444
Study 32052516 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (GLIM)
Number of subjects: 444
Study 35877601 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline (TB drug)
Number of subjects: 380
Study 35877601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretomanid (TB drug)
Number of subjects: 380
Study 35877601 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (HIV drug)
Number of subjects: 380
Study 35877601 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine (HIV drug)
Number of subjects: 380
Study 35877601 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (HCV drug)
Number of subjects: 380
Study 35877601 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (HCV drug)
Number of subjects: 380
Study 35877601 — intervention group
Group type: COMPARATOR
Intervention: TB drugs (Bedaquiline and Pretomanid)
Number of subjects: 380
Study 33978188 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (500 mg/d) for 12 weeks
Number of subjects: 100
Study 33978188 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 100
Study 33120822 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion combined with characteristic lifestyle intervention of TCM
Number of subjects: 150
Study 33120822 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion combined with lifestyle intervention
Number of subjects: 150
Study 33120822 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention only
Number of subjects: 150
Study 35634651 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition representing mental illness across the warmth-competence stereotype space
Number of subjects: 60
Study 35634651 — intervention group
Group type: COMPARATOR
Intervention: Generic measures of discrimination (e.g., social distance scales)
Number of subjects: 60
Study 32841326 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFLD-related genetic risk score (GRS)
Number of subjects: 904
Study 32841326 — intervention group
Group type: EXPERIMENTAL
Intervention: PNPLA3 rs738409
Number of subjects: 904
Study 32841326 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-sample MR
Number of subjects: 904
Study 32851419 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum 25(OH)D concentration
Number of subjects: 341484
Study 32851419 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency or deficiency
Number of subjects: 341484
Study 34165010 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 25OHD <20 ng/ml
Number of subjects: 549
Study 34165010 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 25OHD <10 ng/ml
Number of subjects: 549
Study 32544161 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-way texting (2wT) intervention
Number of subjects: 362
Study 35720026 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-family rehabilitation intervention
Number of subjects: 100
Study 35720026 — intervention group
Group type: COMPARATOR
Intervention: Routine intervention (Control)
Number of subjects: 100
Study 33146457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg once daily)
Number of subjects: 120
Study 33146457 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (30 minutes of interval training 5 days per week)
Number of subjects: 120
Study 33146457 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 120
Study 33146457 — intervention group
Group type: COMPARATOR
Intervention: Control (habitual living)
Number of subjects: 120
Study 35436974 — intervention group
Group type: EXPERIMENTAL
Intervention: WalkingPad app with built-in virtual assistant (Experimental group 2)
Number of subjects: 300
Study 35436974 — intervention group
Group type: EXPERIMENTAL
Intervention: WalkingPad app without built-in virtual assistant (Experimental group 1)
Number of subjects: 300
Study 35436974 — intervention group
Group type: COMPARATOR
Intervention: Practice diary (Active control group)
Number of subjects: 300
Study 35436974 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 300
Study 34107861 — intervention group
Group type: EXPERIMENTAL
Intervention: Gui‐fu‐di‐huang‐wan (GFDHW) treatment and lifestyle intervention
Number of subjects: 60
Study 34107861 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 34107861 — intervention group
Group type: EXPERIMENTAL
Intervention: GFDHW treatment and lifestyle intervention
Number of subjects: 60
Study 34360425 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-Alanine (6.4 g)
Number of subjects: 20
Study 34360425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 34360425 — intervention group
Group type: EXPERIMENTAL
Intervention: Both B-ALA and Placebo
Number of subjects: 20
Study 32978471 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentivized experiments (monetary payments to elicit norms)
Number of subjects: 1656
Study 32978471 — intervention group
Group type: COMPARATOR
Intervention: Self-report scales
Number of subjects: 1656
Study 36205739 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC-302 200 mg twice daily for 12 weeks
Number of subjects: 76
Study 36205739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 32396474 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV disclosure status (Yes/No)
Number of subjects: 371
Study 32396474 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns of disclosure (Broad, Selective, Nondisclosure)
Number of subjects: 371
Study 32396474 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors predicting HIV disclosure
Number of subjects: 371
Study 34978388 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic roxatidine acetate hydrochloride (RAH) sustained-release capsule, 75 mg
Number of subjects: 72
Study 34978388 — intervention group
Group type: COMPARATOR
Intervention: Commercial capsule (ALTAT)
Number of subjects: 72
Study 32703124 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference-based designs (two-stage, fully randomised, and partially randomised)
Number of subjects: 0
Study 32703124 — intervention group
Group type: COMPARATOR
Intervention: Conventional trials
Number of subjects: 0
Study 35373306 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved mental healthcare (MHC)
Number of subjects: 666
Study 35373306 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated interventions (INT)
Number of subjects: 666
Study 35373306 — intervention group
Group type: COMPARATOR
Intervention: Service as usual (SAU)
Number of subjects: 666
Study 32604921 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-fluid supplemented with 8 mM alanyl-glutamine
Number of subjects: 0
Study 32604921 — intervention group
Group type: COMPARATOR
Intervention: Control (PD-fluid without alanyl-glutamine)
Number of subjects: 0
Study 32604921 — intervention group
Group type: EXPERIMENTAL
Intervention: FTIR spectroscopy
Number of subjects: 0
Study 33560875 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 199
Study 33560875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 33189426 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (SNA+VHS)
Number of subjects: 34633
Study 33189426 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norm‐based motivational intervention (SNA)
Number of subjects: 34633
Study 33189426 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention‐based Volitional Help Sheet (VHS)
Number of subjects: 34633
Study 33189426 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual control
Number of subjects: 34633
Study 32950590 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (9 mg/day)
Number of subjects: 62
Study 32950590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 32683828 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision with preservation of Denonvilliers' fascia (iTME)
Number of subjects: 0
Study 32683828 — intervention group
Group type: COMPARATOR
Intervention: Traditional total mesorectal excision (TME)
Number of subjects: 0
Study 36506468 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-start group (aspirin 100 mg daily starting 3 days after operation)
Number of subjects: 250
Study 36506468 — intervention group
Group type: COMPARATOR
Intervention: Normal-start group (no antithrombotic therapy until 30 days after operation)
Number of subjects: 250
Study 32606057 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic-band resistance exercise with HMB supplementation
Number of subjects: 144
Study 32606057 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration treatment with HMB supplementation
Number of subjects: 144
Study 32606057 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 144
Study 34983251 — intervention group
Group type: EXPERIMENTAL
Intervention: AIM HI therapist training for 6 months
Number of subjects: 0
Study 34983251 — intervention group
Group type: COMPARATOR
Intervention: Usual care (observation of routine care)
Number of subjects: 0
Study 34422323 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (75 grams added to diet for 14 days)
Number of subjects: 10
Study 34422323 — intervention group
Group type: COMPARATOR
Intervention: Glucose (75 grams added to diet for 14 days)
Number of subjects: 10
Study 34146511 — intervention group
Group type: EXPERIMENTAL
Intervention: Efgartigimod (10 mg/kg), administered as four infusions per cycle (one infusion per week), repeated as needed depending on clinical response no sooner than 8 weeks after initiation of the previous cycle.
Number of subjects: 167
Study 34146511 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered as matching infusions.
Number of subjects: 167
Study 34146511 — intervention group
Group type: EXPERIMENTAL
Intervention: Efgartigimod
Number of subjects: 167
Study 34146511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 33765453 — intervention group
Group type: EXPERIMENTAL
Intervention: Health systems intervention (three-phase intervention: LTBI programme evaluation, local decision making, and strengthening activities)
Number of subjects: 24
Study 33765453 — intervention group
Group type: COMPARATOR
Intervention: Control (standard LTBI care)
Number of subjects: 24
Study 33765453 — intervention group
Group type: EXPERIMENTAL
Intervention: Health systems intervention
Number of subjects: 24
Study 33326694 — intervention group
Group type: COMPARATOR
Intervention: teriparatide (20 μg/day, daily subcutaneous injection for 6 months)
Number of subjects: 20
Study 33326694 — intervention group
Group type: EXPERIMENTAL
Intervention: combined treatment of WJ‐MSCs (intramedullary [4 × 107 cells] injection and intravenous [2 × 108 cells] injection after 1 week) and teriparatide (20 μg/day, daily subcutaneous injection for 6 months)
Number of subjects: 20
Study 33326694 — intervention group
Group type: COMPARATOR
Intervention: teriparatide alone
Number of subjects: 20
Study 33326694 — intervention group
Group type: EXPERIMENTAL
Intervention: combined treatment of WJ‐MSCs and teriparatide
Number of subjects: 20
Study 34429151 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 51